Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.

Real-world costs increased after patients started/switched to infusible DMTs. Drug cost is the main driver for the total costs, which varied substantially by site of care. Controlling drug cost markups and using home setting for infusion can reduce costs in the treatment of MS patients.